Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy

What is the purpose of this trial?

To determine treatment efficacy defined as histologic regression to CIN 1 or less at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in the HPV Vaccine + Imiquimod group compared to control

Participation Guidelines

Ages: 18 years and older

Gender: Female only

Yale Cancer Center

Start Date: 06/13/2016

End Date: 03/31/2021

Last Updated: 01/03/2019

Study HIC#: 1603017415

Get Involved

For more information about this study, contact:
Lisa Baker
+1 203-785-6398

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image